Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.

Gastroenterology·2026
Same author

What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association.

JHEP reports : innovation in hepatology·2022
Same author

Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial.

Canadian liver journal·2022
Same author

Reminiscences of a soon-to-be ex-hepatologist.

Canadian liver journal·2022
Same author

A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.

Hepatology communications·2022
Same author

The viral hepatitis B care cascade: A population-based comparison of immigrant groups.

Hepatology (Baltimore, Md.)·2021

Related Experiment Video

Updated: May 31, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Hepatocellular carcinoma: screening and staging.

Morris Sherman1

  • 1Department of Medicine, University of Toronto, Toronto General Hospital, 585 University Avenue, Toronto, ON M5G 2N2, Canada. morris.sherman@uhn.on.ca

Clinics in Liver Disease
|June 22, 2011
PubMed
Summary

Active screening for liver cancer (HCC) detects early-stage tumors, enabling curative treatments. Regular ultrasounds and standardized staging are key to reducing mortality and guiding new therapies.

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

Related Experiment Videos

Last Updated: May 31, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

Area of Science:

  • Hepatology
  • Oncology
  • Diagnostic Imaging

Background:

  • Hepatocellular carcinoma (HCC) screening identifies early-stage disease.
  • Early detection improves treatment options and cure rates.
  • High-quality ultrasound at 6-month intervals is crucial for effective screening.

Purpose of the Study:

  • To highlight the benefits of active screening for HCC.
  • To emphasize the role of standardized staging systems.
  • To underscore the importance of patient stratification for clinical trials.

Main Methods:

  • Review of current screening protocols for HCC.
  • Discussion of the Barcelona Cancer of the Liver Clinic (BCLC) staging system.
  • Analysis of the impact of staging on treatment and research.

Main Results:

  • Active screening identifies curable early HCC.
  • Widespread screening can significantly decrease HCC mortality.
  • The BCLC staging system standardizes prognosis and treatment selection.

Conclusions:

  • Early HCC detection through screening offers high cure rates.
  • Standardized staging (BCLC) is essential for consistent care.
  • Patient stratification by BCLC stage is critical for evaluating new targeted therapies.